pharma-ai
(9)
Aktana
Aktana spent years turning pharma’s scattered customer data into a daily recommendation engine. Now, under PharmaForceIQ, its field intelligence is being stitched to digital orchestration in a bid to close one of life sciences’ most expensive gaps.
Ritivel
Ritivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies. Its AI agents draft dense regulatory documents - CTDs, CSRs, INDs, and BLAs - directly in Microsoft Word, following FDA formatting rules and pulling from a company's own clinical data and prior submissions, with every claim cited back to its source. The goal is to compress work that normally takes weeks of manual synthesis into minutes, helping drugs reach patients sooner.
Plex Research
Plex Research is a Cambridge, Massachusetts company building an AI-powered scientific intelligence platform for drug discovery. Its proprietary focal graph technology stitches billions of minimally processed experimental data points from genomics, proteomics, chemical biology and clinical sources into a queryable biomedical knowledge graph, then pairs it with large language models so scientists get evidence-backed answers in seconds - every result traceable to the underlying experiments. Trusted by 40+ pharma and biotech teams, Plex helps researchers identify and evaluate drug targets, uncover hidden pharmacology, and, through its AutoPlex agent, run autonomous multi-step research campaigns.
Reveal HealthTech
Reveal HealthTech is a New York-based AI transformation partner for U.S. healthcare and life sciences organizations. Founded in 2023 and incubated by W Health Ventures and 2070 Health, the company pairs clinical expertise with engineering and design to turn AI concepts into deployed products for hospitals, pharma, and digital health innovators. Its flagship products include BioCanvas for clinical trial recruitment, Prism AI for workflow automation, and CareIQ for care coordination. Reveal raised a $7.2M Series A led by Leo Capital in September 2025 and runs teams across the U.S. and Bengaluru, India.
Dimitrios Skaltsas
Dimitrios Skaltsas is the co-founder and CEO of Intelligencia AI, a New York enterprise software company that uses machine learning and curated biomedical data to estimate the probability that a drug candidate will win regulatory approval. Trained as a lawyer in Athens and London, he spent more than a decade at McKinsey, where he built and led New Ventures' big-data and AI work for pharmaceutical R&D before co-founding Intelligencia with Vangelis Vergetis in 2017. Under his leadership the company raised a Series A, was named one of Forbes's Top AI Companies to Watch, secured a U.S. patent for its probability-of-success assessments, and landed on the Inc. 5000. He is also an Executive in Residence at INSEAD.
Lynx Analytics
Lynx Analytics is a Singapore-founded, AI-native analytics firm built by INSEAD students and professors in 2010 to apply graph theory to hard business problems. Its flagship platform, LynxKite, turns very large datasets into graphs and runs hundreds of graph algorithms - many GPU-accelerated - to power everything from telecom churn prediction and fraud detection to drug discovery. Over the past few years the company has pivoted its focus toward AI-native consulting and products for pharma and life sciences, combining biomedical knowledge graphs, large language models, and NVIDIA's accelerated computing stack.
Weave Bio
Weave Bio is a San Francisco-based, AI-native software company that automates the regulatory paperwork behind drug development. Its platform ingests preclinical and clinical study data and drafts submission-ready documents - INDs, investigator's brochures, clinical study reports and health-authority responses - in eCTD-ready format, cutting timelines that once took months down to hours while keeping human reviewers in the loop. Founded in 2022, Weave serves biotech, pharma, CROs and regulatory consultants, and raised a $20M Series A in October 2025 to bring total funding to roughly $36M.
Inductive Bio
Inductive Bio is a New York-based AI company building a machine learning platform that predicts how small-molecule drugs will behave in the body before they are ever synthesized. By training models on a pre-competitive data consortium shared across biopharma teams, its Beacon models, Compass software, and Indy chemistry assistant help medicinal chemists nominate better development candidates faster - reducing the costly 'whack-a-mole' of balancing potency against ADMET properties in preclinical drug discovery.
Doron Aspitz
Doron Aspitz is the President and CEO of Verix, a Santa Clara-based AI platform that helps pharmaceutical companies optimize their commercial operations through predictive analytics, HCP targeting, and GenAI-powered decision intelligence. A serial entrepreneur with 20+ years in technology leadership, he previously co-founded Blue Pumpkin Software - a workforce management company acquired by Witness Systems for ~$75 million in 2005. At Verix, he has built the Tovana platform, now trusted by global pharma giants including Bayer, Novartis, Roche, and GSK, bringing AI-driven commercial intelligence to the complex world of drug commercialization.